Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: A systematic review and meta-analysis

Clinical Infectious Diseases

Volumn 55, Issue 3, 2012, Pages 371-380

  Asadi, Leyla ^a   Sligl, Wendy I ^a,b   Eurich, Dean T ^b   Colmers, Isabelle N ^b   Tjosvold, Lisa ^c   Marrie, Thomas J ^d   Majumdar, Sumit R ^c  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b University Terrace   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; QUINOLONE DERIVATIVE; ROXITHROMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; GENETIC HETEROGENEITY; HOSPITAL PATIENT; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MACROLIDES; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84863933351     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis414     Document Type: Article

References (41)

1. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010; 122:130-41.
2. Asadi L, Eurich DT, Gamble JM, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Impact of guideline-concordant antibiotics and macrolide/B-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study [published online ahead of print 8 March 2012]. Clin Microbiol Infect 2012; doi:10.1111/j.1469-0691.2012.03783.x.
3. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27-72.
4. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36:389-95.
5. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 2007; 131:466-73.
6. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJAnzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009; 33:153-9.
7. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases [published online ahead of print 22 November 2011]. Eur J Clin Pharmacol 2011.
8. Amsden GW. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55:10-21.
9. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with lowdose erythromycin. Am J Respir Crit Care Med 1998; 157(6 Pt 1): 1829-32.
10. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008; 85:36-41.
11. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178:1139-47.
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.
13. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. J Med Libr Assoc 2006; 94:130-6.
14. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials [published online ahead of print 18 October 2011]. BMJ 2011; 343:d5928.
15. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford. asp. Accessed 3 August 2011.
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997; 315:629-34.
17. Arnold FW, LaJoie AS, Brock GN, et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med 2009; 169:1515-24.
18. Blasi F, Iori I, Bulfoni A, Corrao S, Costantino S, Legnani D. Can CAP guideline adherence improve patient outcome in internal medicine departments? Eur Respir J 2008; 32:902-10.
19. Brandenburg JA, Marrie TJ, Coley CM, et al. Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia. J Gen Intern Med 2000; 15:638-46.
20. Bratzler DW, Ma A, Nsa W. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project. Clin Infect Dis 2008; 47(Suppl 3):S193-201.
21. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003; 123:1503-11.
22. Dambrava PG, Torres A, Valles X, et al. Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome. Eur Respir J 2008; 32:892-901.
23. Frei CR, Koeller JM, Burgess DS, Talbert RL, Johnsrud MT. Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: results from the United States Community-Acquired Pneumonia Project. Pharmacotherapy 2003; 23:1167-74.
24. Frei CR, Restrepo MI, Mortensen EM, Burgess DS. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med 2006; 119:865-71.
25. Lin TY, Lin SM, Chen HC, et al. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia. Chang Gung Med J 2007; 30:321-32.
26. Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. Comparison of betalactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 2007; 51:3977-82.
27. Marras TK, Jamieson L, Chan CK. Inpatient care of communityacquired pneumonia: the effect of antimicrobial guidelines on clinical outcomes and drug costs in Canadian teaching hospitals. Can Respir J 2004; 11:131-7.
28. McCabe C, Kirchner C, Zhang H, Daley J, Fisman DN. Guidelineconcordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med 2009; 169:1525-31.
29. Menendez R, Ferrando D, Valles JM, Vallterra J. Influence of deviation from guidelines on the outcome of community-acquired pneumonia. Chest 2002; 122:612-7.
30. Menendez R, Torres A, Zalacain R, et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 2005; 172:757-62.
31. Minhas R, Walker SAN, Rachlis A. Management of communityacquired pneumonia at a tertiary-care teaching hospital. Can J Hosp Pharm 2007; 60:245-56.
32. Portier H, Brambilla C, Garre M, Paganin F, Poubeau P, Zuck P. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis 2005; 24: 367-76.
33. Querol-Ribelles JM, Tenias JM, Querol-Borras JM, et al. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization. Int J Antimicrob Agents 2005; 25:75-83.
34. Reyes Calzada S, Martinez Tomas R, Cremades Romero MJ, Martinez Moragon E, Soler Cataluna JJ, Menendez Villanueva R. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission. Respir Med 2007; 101:1909-15.
35. Romanelli G, Cravarezza P, Pozzi A, et al. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy. J Chemother 2002; 14:609-17.
36. Welte T, PetermannW, Schurmann D, Bauer TT, Reimnitz P. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005; 41:1697-705.
37. Zervos M, Mandell LA, Vrooman PS, et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med 2004; 3:329-36.
38. Menendez R, Torres A, Reyes S, et al. Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J 2012; 39:156-62.
39. Healy DP. Macrolide immunomodulation of chronic respiratory diseases. Curr Infect Dis Rep 2007; 9:7-13.
40. Giamarellos-Bourboulis EJ, Pechere JC, Routsi C, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 2008; 46:1157-64.
41. Dalhoff A. Immunomodulatory activities of fluoroquinolones. Infection 2005; 33(Suppl 2):55-70.